Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Debt to Equity (2016 - 2023)

Marker Therapeutics (MRKR) has disclosed Debt to Equity for 7 consecutive years, with $0.01 as the latest value for Q1 2023.

  • On a quarterly basis, Debt to Equity changed N/A to $0.01 in Q1 2023 year-over-year; TTM through Mar 2023 was $0.01, a N/A change, with the full-year FY2022 number at $0.13, changed N/A from a year prior.
  • Debt to Equity was $0.01 for Q1 2023 at Marker Therapeutics, down from $0.13 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.29 in Q2 2022 to a low of $0.0 in Q4 2019.
  • A 3-year average of $0.08 and a median of $0.0 in 2019 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 14.84% in 2019; the steepest drop was 98.26% in 2019.
  • Marker Therapeutics' Debt to Equity stood at $0.0 in 2019, then surged by 18038.53% to $0.13 in 2022, then plummeted by 95.2% to $0.01 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Debt to Equity are $0.01 (Q1 2023), $0.13 (Q4 2022), and $0.22 (Q3 2022).